Pyxis Oncology receives FDA Fast Track for PYX-201 in head and neck cancer

Pyxis Oncology, Inc.

FDA granted Fast Track Designation to PYX-201 for recurrent/metastatic HNSCC after prior chemo and anti-PD-(L)1.
PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin in the tumor extracellular matrix.
CEO Lara Sullivan called the designation a significant milestone and said trial recruitment is ongoing.
Fast Track aims to speed development and review for serious conditions with unmet medical need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.